Cargando…
Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial
To investigate the effects of oral bacteriotherapy on intestinal phenylalanine and tyrosine metabolism, in this longitudinal, double-arm trial, 15 virally suppressed HIV+ individuals underwent blood and fecal sample collection at baseline and after 6 months of oral bacteriotherapy. A baseline fecal...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408387/ https://www.ncbi.nlm.nih.gov/pubmed/32635406 http://dx.doi.org/10.3390/metabo10070274 |
_version_ | 1783567820637863936 |
---|---|
author | Innocenti, Giuseppe P. Santinelli, Letizia Laghi, Luca Borrazzo, Cristian Pinacchio, Claudia Fratino, Mariangela Celani, Luigi Cavallari, Eugenio N. Scagnolari, Carolina Frasca, Federica Antonelli, Guido Mastroianni, Claudio M. d’Ettorre, Gabriella Ceccarelli, Giancarlo |
author_facet | Innocenti, Giuseppe P. Santinelli, Letizia Laghi, Luca Borrazzo, Cristian Pinacchio, Claudia Fratino, Mariangela Celani, Luigi Cavallari, Eugenio N. Scagnolari, Carolina Frasca, Federica Antonelli, Guido Mastroianni, Claudio M. d’Ettorre, Gabriella Ceccarelli, Giancarlo |
author_sort | Innocenti, Giuseppe P. |
collection | PubMed |
description | To investigate the effects of oral bacteriotherapy on intestinal phenylalanine and tyrosine metabolism, in this longitudinal, double-arm trial, 15 virally suppressed HIV+ individuals underwent blood and fecal sample collection at baseline and after 6 months of oral bacteriotherapy. A baseline fecal sample was collected from 15 healthy individuals and served as control group for the baseline levels of fecal phenylalanine and tyrosine. CD4 and CD8 immune activation (CD38(+)) was evaluated by flow cytometry. Amino acid evaluation on fecal samples was conducted by Proton Nuclear Magnetic Resonance. Results showed that HIV+ participants displayed higher baseline phenylalanine/tyrosine ratio values than healthy volunteers. A significand reduction in phenylalanine/tyrosine ratio and peripheral CD4(+) CD38(+) activation was observed at the end of oral bacteriotherapy. In conclusion, probiotics beneficially affect the immune activation of HIV+ individuals. Therefore, the restoration of intestinal amino acid metabolism could represent the mechanisms through which probiotics exert these desirable effects. |
format | Online Article Text |
id | pubmed-7408387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74083872020-08-13 Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial Innocenti, Giuseppe P. Santinelli, Letizia Laghi, Luca Borrazzo, Cristian Pinacchio, Claudia Fratino, Mariangela Celani, Luigi Cavallari, Eugenio N. Scagnolari, Carolina Frasca, Federica Antonelli, Guido Mastroianni, Claudio M. d’Ettorre, Gabriella Ceccarelli, Giancarlo Metabolites Article To investigate the effects of oral bacteriotherapy on intestinal phenylalanine and tyrosine metabolism, in this longitudinal, double-arm trial, 15 virally suppressed HIV+ individuals underwent blood and fecal sample collection at baseline and after 6 months of oral bacteriotherapy. A baseline fecal sample was collected from 15 healthy individuals and served as control group for the baseline levels of fecal phenylalanine and tyrosine. CD4 and CD8 immune activation (CD38(+)) was evaluated by flow cytometry. Amino acid evaluation on fecal samples was conducted by Proton Nuclear Magnetic Resonance. Results showed that HIV+ participants displayed higher baseline phenylalanine/tyrosine ratio values than healthy volunteers. A significand reduction in phenylalanine/tyrosine ratio and peripheral CD4(+) CD38(+) activation was observed at the end of oral bacteriotherapy. In conclusion, probiotics beneficially affect the immune activation of HIV+ individuals. Therefore, the restoration of intestinal amino acid metabolism could represent the mechanisms through which probiotics exert these desirable effects. MDPI 2020-07-03 /pmc/articles/PMC7408387/ /pubmed/32635406 http://dx.doi.org/10.3390/metabo10070274 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Innocenti, Giuseppe P. Santinelli, Letizia Laghi, Luca Borrazzo, Cristian Pinacchio, Claudia Fratino, Mariangela Celani, Luigi Cavallari, Eugenio N. Scagnolari, Carolina Frasca, Federica Antonelli, Guido Mastroianni, Claudio M. d’Ettorre, Gabriella Ceccarelli, Giancarlo Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial |
title | Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial |
title_full | Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial |
title_fullStr | Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial |
title_full_unstemmed | Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial |
title_short | Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial |
title_sort | modulation of phenylalanine and tyrosine metabolism in hiv-1 infected patients with neurocognitive impairment: results from a clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408387/ https://www.ncbi.nlm.nih.gov/pubmed/32635406 http://dx.doi.org/10.3390/metabo10070274 |
work_keys_str_mv | AT innocentigiuseppep modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT santinelliletizia modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT laghiluca modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT borrazzocristian modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT pinacchioclaudia modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT fratinomariangela modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT celaniluigi modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT cavallarieugenion modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT scagnolaricarolina modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT frascafederica modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT antonelliguido modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT mastroianniclaudiom modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT dettorregabriella modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial AT ceccarelligiancarlo modulationofphenylalanineandtyrosinemetabolisminhiv1infectedpatientswithneurocognitiveimpairmentresultsfromaclinicaltrial |